The molecularly targeted oncologics that have energized oncology drug development and treatment over the last decade have sparked a secondary boom in companion diagnostics. After all, a drug for a tumor expressing a particular receptor profile is not particularly useful unless physicians can identify patients with that profile.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
